Navigation Links
Researchers aim for consensus on measuring the impact of visual impairment
Date:4/1/2010

Rockville, MD New guidelines that outline best practices for measuring the economic burden of visual impairment will make it easier for the policy, science and medical communities to draw conclusions and compare results across studies.

The guidelines arose from a working group convened by the Association for Research in Vision and Ophthalmology (ARVO) and the International Agency for the Prevention of Blindness (IAPB). They were published this month in the ARVO journal Investigative Ophthalmology and Visual Science (The Cost of Visual Impairment: Purpose, Perspectives, and Guidance).

The group, representing participants from around the world and from major vision research organizations, came together to review the methods used in two US studies and one Australian study and to develop a consensus on appropriate methods to employ in future studies on the cost of vision impairment regardless of where they are conducted.

"When estimates of the cost of visual impairment vary over time or across countries," explains Johns Hopkins University researcher Kevin Frick, PhD, the lead author, "policy makers are left to ponder whether one estimate differs from another because of changes in the population, changes in the impact of the disease or changes in the methods. Researchers can help policy makers by removing one of the potential variables changes in methods."

In September 2007 ARVO and IAPB organized the Vancouver Economic Burden of Vision Loss Group to examine the various methods used to measure visual impairment impact and recommend best practices. The panel of 12 leading vision researchers and health care professionals proposed seven guidelines, summarized as follows:

  1. A comprehensive list of costs includes monetary expenditures on health care (hospital, outpatient, and other), monetary expenditures on things other than health care, loss of patient productivity, loss of family member productivity, deadweight losses and loss of patient wellbeing.

  2. In any assessment of either prevalent or incident costs, the authors should identify the specific items included under the major categories in recommendation 1.

  3. Costs should be presented as separate line items to facilitate comparisons among studies.

  4. A default position is to use a single discount rate for all calculations in an analysis.

  5. The assumed value of purchasing a DALY or QALY should be clearly stated and justified.

  6. It is essential to indicate the perspective of costs included.

  7. The decision-making context and starting point of the analysis should be clear. A statement of whether and how the analysis will be used as part of other analyses is essential.

According to co-author Steven Kymes, PhD, of Washington University in St. Louis, "Higher quality studies using a methodology that consistently follows guidelines will help decision makers and advocates in the ophthalmology community to better understand the magnitude of the impact of visual impairment, how it is likely to change with demographic changes and no additional interventions, and how additional interventions can change the impact over time."

Dr. Frick says the next task is ensuring that the guidelines are disseminated within the research community. Hosting a workshop at an industry conference and sharing the recommendations in additional ophthalmology journals would enhance awareness of the guidelines and support efforts to adopt their practice.

"Following consensus-based guidelines will also make it easier for those asking questions about the impact of visual impairment to know that they are receiving high quality estimates," says Dr. Frick. "And those who are involved in the process of making sure only high quality proposals are funded and only high quality manuscripts get published will have an easier task."


'/>"/>

Contact: Jo Olson
jolson@arvo.org
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Related medicine news :

1. UCSF Researchers Identify Regulator of Human Sperm Cells
2. Researchers find broad spectrum antiviral that fights multitude of viruses
3. University of Alberta researchers develop drug interface to save lives
4. Caregivers of ICU patients are collateral damage of critical illness, say Pitt researchers
5. Researchers fight world hunger by mapping the soybean genome
6. HIV researchers solve key puzzle after 20 years of trying
7. UC Davis researchers identify brain protein for synapse development
8. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
9. Researchers find new way to study how enzymes repair DNA damage
10. UCLA researchers image earliest signs of Alzheimers, before symptoms appear
11. Researchers find leukemia cells metabolize fat to avoid cell death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with ... at 1:00 pm ET. This conference discusses strategies to prevent readmissions in light ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, ... Spice", it has been used for thousands of years. , "The West has caught ... of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... NetZoom subscribers can request new equipment shapes for free and download shapes and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... its market value in 2016. There are currently three proton therapy centers ... to treat more patients. In Italy , the first ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
Breaking Medicine Technology: